Bellecapital International Ltd. Has $4.99 Million Stake in Pfizer Inc. $PFE

Key Points

• Bellecapital International Ltd. raised its stake in Pfizer by 8.9% during the second quarter, bringing its total to 205,972 shares valued at $4.99 million.
• Pfizer reported strong earnings, with $0.78 earnings per share for the last quarter, exceeding estimates and marking a 10.3% year-over-year revenue increase to $14.65 billion.
• The company announced a quarterly dividend of $0.43 per share, yielding around 7.1%, to be paid out on December 1st.

Bellecapital International Ltd. increased its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 8.9% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 205,972 shares of the biopharmaceutical company's stock after purchasing an additional 16,768 shares during the quarter. Bellecapital International Ltd.'s holdings in Pfizer were worth $4,993,000 as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its stake in Pfizer by 0.9% in the first quarter. Vanguard Group Inc. now owns 523,165,127 shares of the biopharmaceutical company's stock valued at $13,257,004,000 after acquiring an additional 4,629,976 shares during the last quarter. Northern Trust Corp lifted its stake in Pfizer by 6.8% in the first quarter. Northern Trust Corp now owns 62,325,957 shares of the biopharmaceutical company's stock valued at $1,579,340,000 after acquiring an additional 3,943,397 shares during the last quarter. Amundi raised its position in shares of Pfizer by 43.4% in the first quarter. Amundi now owns 52,090,403 shares of the biopharmaceutical company's stock valued at $1,265,277,000 after purchasing an additional 15,758,846 shares during the period. Invesco Ltd. raised its position in shares of Pfizer by 2.8% in the first quarter. Invesco Ltd. now owns 30,296,337 shares of the biopharmaceutical company's stock valued at $767,709,000 after purchasing an additional 838,198 shares during the period. Finally, Deutsche Bank AG raised its position in shares of Pfizer by 7.0% in the first quarter. Deutsche Bank AG now owns 28,239,197 shares of the biopharmaceutical company's stock valued at $715,581,000 after purchasing an additional 1,846,436 shares during the period. Institutional investors and hedge funds own 68.36% of the company's stock.

Pfizer Stock Down 0.5%

Shares of NYSE PFE opened at $24.39 on Thursday. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $29.82. The company's 50 day moving average price is $24.89 and its 200-day moving average price is $24.13. The company has a market capitalization of $138.69 billion, a P/E ratio of 12.98, a price-to-earnings-growth ratio of 0.81 and a beta of 0.55.

Pfizer (NYSE:PFE - Get Free Report) last released its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The company had revenue of $14.65 billion for the quarter, compared to the consensus estimate of $13.43 billion. During the same quarter in the previous year, the company earned $0.60 EPS. Pfizer's quarterly revenue was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Equities analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 7th will be issued a dividend of $0.43 per share. The ex-dividend date is Friday, November 7th. This represents a $1.72 annualized dividend and a yield of 7.1%. Pfizer's dividend payout ratio is presently 91.49%.

Wall Street Analysts Forecast Growth

PFE has been the topic of several research analyst reports. Wall Street Zen lowered shares of Pfizer from a "buy" rating to a "hold" rating in a research report on Sunday, September 28th. Morgan Stanley lowered their price target on shares of Pfizer from $33.00 to $32.00 and set an "equal weight" rating on the stock in a research report on Friday, October 10th. Weiss Ratings reissued a "hold (c-)" rating on shares of Pfizer in a report on Wednesday, October 8th. Citigroup raised their target price on shares of Pfizer from $25.00 to $26.00 and gave the company a "neutral" rating in a report on Wednesday, August 6th. Finally, Bank of America lifted their price target on shares of Pfizer from $28.00 to $30.00 and gave the company a "neutral" rating in a report on Friday, October 3rd. Two equities research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have assigned a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus price target of $28.35.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.